Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus

Part of paid clinical trials in Jacksonville, Florida.

Sponsor
Mayo Clinic
Study ID
NCT04256759
Phase
PHASE2
Status
Completed

Conditions

  • Pruritus

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To investigate the potential efficacy of dupilumab in the treatment of moderate to severe chronic hepatic pruritus.

Key Dates

Start date
Sep 1, 2020
Status verified
Nov 2025
Primary completion
Sep 6, 2024
Completion
Sep 6, 2024

Study Design

Enrollment
9 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Dupilumab
    Subcutaneous (SC) dupilumab selected for this study is 300 mg every 2 weeks for 18 weeks.

Primary Outcome Measure

Change in Peak Pruritus Numerical Rating Score (PRNS) [ Time Frame: Baseline; 20 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo Clinic FloridaJacksonvilleFlorida32224-

Find similar trials in Jacksonville, FL

By research site
Mayo Clinic Florida· Jacksonville, FL

Related Studies